APcK110_product_DataBase

Bioactivity	APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis[1].
Invitro	APcK110 (0-500 nM; 0-72 h) 抑制 AML 细胞活力和增殖。APcK110 优先抑制 KIT 突变的 BaF3 细胞株[1]。APcK110 (0-500 nM; 30 min) 抑制 Kit、Stat3、Stat5 和 Akt 的磷酸化[1]。APcK110 (500 nM; overnight) 诱导 OCI/AML3 细胞 caspase 依赖性凋亡[1]。APcK110 (50-500 nM; 7 days) 抑制 AML 原细胞集落形成细胞增殖[1]。 Cell Proliferation Assay[1] Cell Line:
In Vivo	APcK110 (500 nM; i.p.; every other day for 60 days) 在小鼠中显示抗 AML 活性[2]。 Animal Model:
Name	APcK110
CAS	1001083-74-4
Formula	C20H16FN3O2
Molar Mass	349.36
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Faderl S, et al. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009 May 1;69(9):3910-7. [2]. Faderl S, et al. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. 2011 Oct;29(5):1094-7.

PeptideDB